Topic: Johnson & Johnson
The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for carisbamate, an anti-epileptic drug in development, announced Ortho-McNeil-Janssen Pharmaceuticals, Inc.. The NDA, filed in October 2008 by Johnson & Johnson Pharmaceutical Research and ...
Johnson & Johnson: * Johnson & Johnson Pharmaceutical Research & Development submits new . drug application to FDA for Carisbamate . * Johnson & Johnson Pharmaceutical Research & Development says seeks approval for use in epilepsy as adjunctive treatment in partial onset ...
